Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Perio Exam 2 > WBC > Flashcards

WBC Flashcards

1
Q

Lymphomas are

A

malignant proliferations of cells native to lymphoid tissue – lymphocytes and their precursors and derivatives.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Lymphomas usually arise in

A

lymphoid tissue, and can spread to involve solid tissue, marrow, and blood.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Lymphomas are categorized into two main types–

A

Hodgkin and non-Hodgkin lymphomas.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Leukemias are malignant proliferations of cells native to the

A

bone marrow, which often spillover into the blood. Leukemias can spread to involve solid organs (usually liver and spleen).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Until 1973, ethnic pigmentation was

A

unhealthy - if it wasn’t pink, it’s bad. This has gone by.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

The distinction between lymphoma and the lymphocytic leukemias can be difficult in some instances, since in advanced states both can involve

A

lymphoid tissue at any site.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Hodgkin lymphoma: This is a characteristic type of lymphoma defined morphologically by the presence of

A

Reed-Sternberg cells admixed with a variable inflammatory infiltrate.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Unlike non-Hodgkin lymphomas, Hodgkin lymphoma (HL) is often accompanied by

A

fever, arises in a single lymph node or chain of nodes, is more common in young adults (average age 30 years), and is characterized by contiguous spread within lymph node groups (for this reason, staging is particularly important in assessing prognosis).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

The cause of Hodgkin lymphoma is unknown, but

A

EBV has been implicated in playing a role.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Hodgkin Lymphoma: Cell of Origin: The neoplastic cell is the

A

Reed-Sternberg (RS) cell, a distinctive large cell with mirror image nuclei and prominent nucleoli.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Usually only small numbers of RS cells are present in the

A

involved node.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

A diagnosis of Hodgkin lymphoma requires the presence of RS cells in the appropriate

A

histologic background: RS-like cells alone are not specific, and may be seen in non-neoplastic disorders like infectious mononucleosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

RS cells may arise from specialized

A

antigen-presenting cells in lymph nodes; the precise origin of the RS cell remains uncertain. I

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

in some cases the Epstein-Barr virus genome can be identified in the

A

RS cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Hodgkins:

Classification (Grading):

A

Several variants of Hodgkin lymphoma are recognized each with their own common clinical presentations, histologic features, and (to a certain extent) prognosis. Spread of disease is predictable: lymph nodes,spleen
Liver, bone marrow.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Staging: Staging is used to determine treatment and prognosis
1.

A

I - Tumor in one anatomic region or two contiguous anatomic regions on the same side of the diaphragm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Staging: 2

A

II - Tumor in more than two anatomic regions or two non-contiguous regions on the same side of the diaphragm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Staging 3:

A

III - Tumor on both sides of the diaphragm not extending beyond lymph nodes, spleen or Waldeyer’s ring

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Staging 4:

A

IV - Tumor in bone marrow, lung, etc.- any organ site outside of the lymph nodes, spleen or Waldeyer’s ring

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

“B” signs/symptoms:

Hodgkins

A

Fever, night sweats, and significant unexplained weight loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Low-stage disease denotes

A

localized lymph node involvement, without systemic signs (fever, weight loss), and has a better prognosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

High-stage disease indicates

A

widespread disease, often with bone marrow involvement, and has a worse prognosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Choice of therapy (chemotherapy, radiotherapy, or both) and prognosis are based on

A

stage.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

More aggressive forms of disease typically present in

A

higher stages.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Treatment consists of a combination of

A

chemotherapy and, to a less extent today, radiotherapy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

All stages are further divided on the basis of

A

absence (A) or presence (B) of systemic symptoms, including fever, night sweats, and significant unexplained weight loss (terminology example: stage IIIA).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Hodgkins Bimodal age distribution:

A

20-30 years old and >50 years old, ~8,300 cases in 2017, Painless lymphadenopathy (often cervical, supraclavicular, mediastinal), Splenomegaly (detected by MRI)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Hodgkins: Most patients have

A

enlarged, painless, superficial lymph node in
ivolvement as the initial manifestation of disease. Involvement of other lymph nodes in the chest and abdomen can occur, but is less common at presentation, except in lymphocyte-depleted type.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Hodgkins: Involvement of the spleen and liver increase

A

the stage, and are assessed by MRI.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Hodgkins: Complications with

A

infections (decreased cell-mediated immunity), anemia, and thrombocytopenia can occur in advanced disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Combination chemotherapy and, to a lesser extent, radiotherapy have

A

dramatically improved the survival in HD.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

There is a low, but definite risk for developing

A

acute leukemia after treatment with chemotherapy and radiotherapy because of the bone marrow toxicities of the chemotherapeutic drugs used.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Prognosis - hodgkins

5-year survival - Stage 1 and IIa

A

Stage I and IIA - almost 100%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Hodgkins: 5-year survival rate in Stage IV is

A

50%

“B” signs/symptoms associated with worse prognosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Stage III and IV disease more likely to have

A

“B” symptoms (worse prognosis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Non-Hodgkin lymphomas (NHL) arise in

A

lymphoid tissue – either in lymph nodes or lymphoid tissue of solid organs- and have the capacity to spread into other nodes, solid organs, bone marrow, and blood.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

NHL: Over 2 dozen

A

types are currently recognized. Most (85%) are of B cell origin. Most of remainder are of T cell origin
Incidence rises steadily after age 40, approximately 72,000 cases in 2017.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

NHL :There is more morphologic diversity in NHL than in

A

HD, and more than two dozen subtypes of NHL are recognized for purposes of determining prognosis and selecting therapy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

NHL: 8 of the subtypes comprise over

A

90% of the NHLs in the US.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

In contrast to HD, NHLs tend to have

A

multiple node involvement, more frequent extranodal spread and peripheral blood involvement, and affect all ages.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Like HD, histologic examination of involved tissue is

A

required for diagnosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Cell of Origin: The majority (85%) of NHL are

A

clonal neoplasms of B lymphocytes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

B lymphocytes are those lymphocytes specialized for

A

antibody production.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

The remainder of NHL are of

A

T cell origin (15%).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

B-lymphocytes normally have the capacity to differentiate into

A

plasma cells (the most mature B cell) as part of the immune response, just as T-lymphocytes become activated as part of the normal immune response.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

A lymphoma develops when there is a

A

monoclonal expansion of lymphocytes that have been “arrested” (or have acquired a genetic rearrangement that alters growth regulation) at a particular stage in transformation. The clonal cells proliferate without normal regulatory mechanisms.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

Thus, all lymphoid neoplasms are considered to arise from a

A

single transformed cell. daughter cells synthesize antigen receptor proteins identical to the original cell that reflect a “frozen” state of B cell maturation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

(hypogammaglobulinemia,

A

increased risk of infection).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

NHLs are classified on the basis of their

A

morphology (microscopic appearance), cell of origin (immunophenotype), clinical features, and genotype.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

The World Health Organization convenes panels of lymphoma experts to examine the accuracy and utility of the classification system, and the most recent system, published in 2008, is based on the

A

Revised European-American Lymphoma classification that was first proposed in the mid-1990’s.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

Staging: NHL: Similar to Hodgkin lymphoma. There is less correlation between

A

stage and prognosis in NHL than in HD. Cell type and tumor proliferative index are better correlated with prognosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

NHL: • Localized disease indicates what stage-

A

low stage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

• NHL - Numerous sites of involvement or bone marrow involvement indicates what stage-

A

high stage

54
Q

• NHL - Prognosis often based more on which criteria?

A

sub-type of lymphoma than stage (exception to the general rule, “grading” or subtyping is critical with NHL)

55
Q

NHL Clinical Features and Course: Presentation is usually with .

A

painless enlarged lymph nodes, or evidence of extranodal spread- enlarged liver or spleen.

56
Q

Bone marrow involvement is more common in NHL than in

A

HD, and lymphoma cells may circulate in peripheral blood.

57
Q

NHL - Circulating lymphoma cells in the peripheral blood represent a

A

‘leukemic phase’ of the disease, in distinction to the group of diseases classified as leukemias.

58
Q

NHL - The disease can spread to involve

A

solid organs, GI tract, bones, and nervous system.

59
Q

Enlargement of lymph node groups can produce

A

vascular and lymphatic obstruction. Complications with infections, anemia, and thrombocytopenia occur.

60
Q

NHL Treatment involves

A

chemotherapy, and less often, radiotherapy. Bone marrow transplant may be used for highly resistant disease, allowing higher doses of chemotherapy to be delivered with the hope of a cure

61
Q

Leukemias are malignant neoplasms of

A

hematopoietic tissue that arise in the bone marrow. The malignant cells proliferate in the bone marrow, commonly producing a pattern of diffuse infiltration.

62
Q

Leukemias: There is often “spill over” of the proliferating cells into the

A

blood and other organs.

63
Q

Leukemias: Classification: This group of diseases can be roughly conceptualized both in terms of

A

onset and of cell type involved. Disease onset can be acute (rapid) or chronic (indolent), and cell types include myelogenous (myeloid and monocytic) and lymphoid.

64
Q

What are the types of leukemias we need to know?

A

acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myelogenous leukemia (AML), and chronic myelogenous leukemia (CML).

65
Q

Leukemia classification becomes increasingly complex as a

A

greater number of tests become available to evaluate specific morphologic, enzymatic, immunologic, and genetic aspects of the malignant cells.

66
Q

Acute leukemias:

A

Rapid, usually fatal in months
Mostly blasts (immature cells)
WBC increased normally, 30% show decrease
Bone marrow: >20% blasts

67
Q

Chronic Leukemias

A

Indolent, often long survival
Mostly mature cells
Often increased WBC
Blasts not increased in Bone marrow

68
Q

• Acute lymphoblastic leukemia (ALL): The proliferating cell is a

A

primitive lymphoid cell. This type of leukemia accounts for about 40% of the acute leukemias, and is the most frequent type in children <15 years old.

69
Q

ALL: It is the principal cause of cancer deaths in

A

childhood, with a peak incidence at age 4, but ALL can affect persons of all ages.

70
Q

ALL: Five subtypes

A

(early B precursor, pre-B, mature B, and T cell) are recognized immunologically.

71
Q

ALL: Cytogenetic analysis has

A

prognostic significance, with hyperdiploidy (>50 chromosomes per leukemic cell) being the subtype with best prognosis (most are children)

72
Q

ALL: Prognosis related to cytogenetics,

A

Adults often have bad prognosis, Chemotherapy is mainstay of treatment with bone marrow transplantation considered at relapse

73
Q

Enlargement of lymph nodes, liver and spleen is more common in ALL than

A

AML.

74
Q

ALL often involves the

A

central nervous system.

75
Q

ALL: The best prognosis group is

A

children aged 2-10 with pre-B cell type.

76
Q

Acute myelogenous leukemia (AML): The proliferating cell is a

A

primitive myeloid cell.

77
Q

AML: Several subtypes exist based on

A

morphology, cytochemistry, immunophenotype and cytogenetics.

78
Q

AML: Increased WBC count often accompanied by

A

anemia and thrombocytopenia.

79
Q

AML: More common in

A

adults

80
Q

AML: Cytoplasmic evidence of myeloid differentiation includes the

A

presence of several types of granules (myeloperoxidase) found in more mature myeloid cells.

81
Q

AML: Cytoplasmic inclusions called Auer rods, when present, are

A

diagnostic.

82
Q

Many subtypes of AML can be recognized based on

A

morphology, cytochemistry, immunophenotype and karyotype.

83
Q

AML - The karyotype is most predictive of

A

prognosis.

84
Q

AML usually affects an older adult population, with a median age of

A

50 years.

85
Q

AML - Sometimes the lesional cells will proliferate in

A

soft tissue (including the gingivae), producing what is termed granulocytic sarcoma.

86
Q

AML = Although many patients can obtain remission of disease after chemotherapy, the duration of remission is often

A

transient.

87
Q

—————- transplant is the current therapy undergoing evaluation/trial for treatment of refractory patients as well as those in first remission from standard chemotherapy, and is a potentially curative procedure.

A

Bone marrow

88
Q

• Chronic Lymphocytic Leukemia (CLL): The proliferating cell is a

A

mature-appearing, but immunologically incompetent, lymphocyte.

89
Q

Immunologically CLL cells can be proven to be

A

monoclonal (derived from the same precursor cell) and within a given patient all have identical cell surface phenotype.

90
Q

CLL: More than 95% are of

A

B cell type, and most commonly express IgM kappa surface immunoglobulin.

91
Q

CLL cells have

A

High expression of BCL2

92
Q

• CLL accounts for about 2/3 of

A

chronic leukemias, and is most common in adults over 60, with a male:female ratio of 2:1.

93
Q

The course of the disease of CLL is

A

indolent, and patients may not require treatment during the early stages.

94
Q

CLL: As the monoclonal lymphocytes proliferate and migrate to other lymphoid sites there can be involvement of

A

spleen, liver, and lymph nodes.

95
Q

Peripheral leukocytosis is common in

A

CLL, , and can be 5-10x normal.

96
Q

Eventually cytopenias may develop (anemia and thrombocytopenia)

A

in CLL as the marrow is overrun by leukemic cells.

97
Q

CLL: Because the neoplastic lymphocytes do not respond to antigenic stimuli,

A

hypogammaglobulinemia develops in most patients.

98
Q

CLL: Chemotherapy is the basis of treatment. Median survival is

A

4-6 years.

99
Q

Chronic Myelogenous Leukemia (CML): The proliferating cell is an

A

immature hematopoietic cell, a stem cell from which all other hematopoietic cells arise.

100
Q

CML: Clonal proliferation of

A

immature granulocytes - a stem cell disorder. Marked increase in white blood cell count with eosinophilia and or basophilia, left-shifted granulocytes

101
Q

CML: May have

A

thrombocytosis and anemia. Splenomegaly is typically present.

102
Q

IN CML: The stem cell pool is increased

A

10-20x normal, and although the cells can mature, there is failure to respond to normal regulators of growth.

103
Q

CML: Typically there is a marked increase in

A

peripheral white cell count, with all myeloid cell types present (especially myelocytes, eosinophils, and basophils).

104
Q

CML: A specific chromosomal abnormality, the Philadelphia chromosome [t(9;22)], occurs in

A

all the proliferating cells. The chromosomal abnormality results in fusion of the BCR-ABL genes, which mimic the effects of growth factor activation, driving the proliferation of CML.

105
Q

While this fusion gene is always present in CML, it is not

A

unique to this disorder.

106
Q

CML accounts for about 1/3 of

A

chronic leukemias, and usually occurs in adults from 25-60 years of age.

107
Q

Enlargement of the spleen due to proliferation of abnormal cells is almost always present with

A

CML

108
Q

CML: The terminal phase of the disease marked by a relative increase in

A

immature cells in peripheral blood and bone marrow, and decreased response to treatment, is known as blast crisis. This stage is equivalent to an acute leukemia, and is of myeloid lineage in 2/3 and of lymphoid lineage in 1/3.

109
Q

CML: Initial therapy is with targeted inhibitors of the

A

BCR-ABL tyrosine kinase, which induce complete remission in a high percentage of patients.

110
Q

CML: With relapsed or resistant disease,

A

bone marrow transplant may be performed, although this is risky in older patients.

111
Q

Clinical Features of Leukemia: Clinical features result from:

A

(1) impairment of marrow function as abnormal cells suppress growth of normal cells, and (2) infiltration of body organs due to proliferation of the abnormal cells.

112
Q

Leukemia: Anemia is manifest as

A

pallor, weakness, and fatigue.

113
Q

Leukemia: Thrombocytopenia

A

(decreased platelets) produces bleeding and bruises.

114
Q

Leukemia: Infections result from decreased production of mature

A

granulocytes and production of non-functional granulocytes and/or lymphocytes.

115
Q

Leukemia: Fever can be due to

A

infection or increased metabolism of proliferating cells.

116
Q

Leukemia: Organ enlargement (lymph nodes, spleen, liver) occurs as the

A

abnormal cells proliferate in these sites.

117
Q

Leukemia: Infiltration of the gingivae is a feature commonly associated with

A

acute myelo-monocytic leukemias.

118
Q

Plasma cell disorders result from clonal expansion of

A

immunoglobulin-secreting cells.

119
Q

The secreted immunoglobulin (or portion of immunoglobulin) results in increases in

A

serum monoclonal protein (M component) which may have adverse effects on renal and neurologic function.

120
Q

Multiple Myeloma: The proliferating cell is a

A

plasma cell that produces immunoglobulin. Because this is a clonal disorder, only one immunoglobulin type is produced by the neoplastic cells. In 60% this is IgG; in 20-25%, IgA; in the remainder it is only kappa or lambda light chain; rarely it is IgM, IgD, or IgE.

121
Q

Multiple myeloma: When only light chains are produced, patients can excrete the

A

low molecular weight light chains in the urine (Bence Jones proteinuria).

122
Q

Multiple myeloma: In some patients, complete monoclonal immunoglobulin is present as well as

A

excess light chains in urine.

123
Q

Multiple Myeloma: Multifocal destructive bone lesions characterize

A

myeloma.

124
Q

Multiple Myeloma: Bone resorption results from secretion of

A

osteoclast activating factors by the myeloma cells.

125
Q

Multiple Myeloma: Proteinaceous casts may form in the

A

kidneys (myeloma kidney).

126
Q

Multiple Myeloma: ——— is often present, and ——— may form from the monoclonal protein.

A

Hypercalcemia, amyloid

127
Q

Mutliple Myeloma 30,000 cases are projected to be diagnosed in 2016 in the US, with an average patient being

A

70 years old.

128
Q

Multiple Myeloma: Patients often present with

A

bone pain, hypercalcemia, and renal disease.

129
Q

Multiple myeloma: As the tumor cells proliferate, complications with recurrent infections, anemia, and thrombocytopenia develop due to

A

destruction of normal marrow by the tumor.

130
Q

Multiple myeloma: Documenting monoclonal protein and skeletal lesions makes the .

A

diagnosis

Perio Exam 2 (20 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions